Summary
(The study at this site is closed, please see the NCT link if you are looking for more information) The ARST2031 study is a medical research trial designed to find better treatments for a rare and serious cancer called high-risk rhabdomyosarcoma (HR-RMS). This cancer affects muscles and is most common in children and teenagers. Even with strong treatments, many patients still have a low chance of staying cancer-free for 3 years.
Description
Patients with high-risk rhabdomyosarcoma (HR-RMS) continue to have poor outcomes with 3-year event free survival (EFS) rates of 30% or less despite dose intensification on the most recent cooperative group RMS trials. Vinorelbine (VINO) has demonstrated clinical activity in RMS patients with relapsed and refractory disease and has been shown to provide a survival benefit when given as maintenance chemotherapy along with oral cyclophosphamide for a select group of patients who have achieved a complete remission. In an attempt to improve long term survival for patients with HR-RMS, ARST2031 will evaluate vinca alkaloid intensification and maintenance therapy. Patients will be randomly assigned to vincristine, dactinomycin and cyclophosphamide (VAC) followed by maintenance with vinorelbine and oral cyclophosphamide (VINO-CPO) or vinorelbine, dactinomycin and cyclophosphamide (VINO-AC) followed by maintenance with VINO-CPO. Safety and feasibility of VINO-AC will be assessed in the first 8 patients prior to randomization. Correlative biology studies will be performed.
Principal Investigator
Faculty Contact
Kristi Sutphin - kristi.sutphin@vandaliahealth.org
Research Contact
Sana Farooki - sana.farooki@vandaliahealth.org